

Resource Summary Report

Generated by [T1D](#) on Aug 1, 2026

MUGA

RRID:SCR_014072

Type: Tool

Proper Citation

MUGA (RRID:SCR_014072)

Resource Information

URL: <http://csbio.unc.edu/CCstatus/index.py?run=Geneseek>

Proper Citation: MUGA (RRID:SCR_014072)

Description: MUGA genotypes for 458 samples from the developing CC lines described in the February 2012 issue of Genetics. Genotypes for 168 reference strains that include biological and technical replicates for the the 8 CC founder strains and their F1 crosses are also provided. Genotype calls are those reported by Illumina. All results are provided as comma separated files with one row per marker. Each marker is identified by a probe name and its genomic position in NCBI Build 37.

Resource Type: data set, data or information resource

Defining Citation: [PMID:22345608](#)

Keywords: genetic, genotype, reference strain, cc line

Resource Name: MUGA

Resource ID: SCR_014072

Record Creation Time: 20220129T080318+0000

Record Last Update: 20260801T042724+0000

Ratings and Alerts

No rating or validation information has been found for MUGA.

No alerts have been found for MUGA.

Data and Source Information

Usage and Citation Metrics

We found 262 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Sobrinho S, et al. (2025) Severe inflammation and lineage skewing are associated with poor engraftment of engineered hematopoietic stem cells in patients with sickle cell disease. *Nature communications*, 16(1), 3137.

Preusser M, et al. (2025) Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial. *Nature medicine*, 31(8), 2797.

Walters MC, et al. (2025) Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease. *Blood advances*, 9(5), 955.

Arora A, et al. (2025) A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC). *Trials*, 26(1), 73.

Shortreed H, et al. (2025) Evaluating the Necessity and Impact of Cardiac Imaging on Breast Cancer Care in Northwestern Ontario. *Cancers*, 17(12).

Maio M, et al. (2025) First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors. *Journal for immunotherapy of cancer*, 13(8).

Nasca V, et al. (2025) Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial. *BMC cancer*, 25(1), 633.

Cascone T, et al. (2025) Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial. *Nature medicine*, 31(8), 2788.

Torrado J, et al. (2025) Prevalence of frequent premature ventricular contractions and left-ventricular systolic dysfunction in patients receiving Holter monitoring. *Journal of cardiovascular electrophysiology*, 36(1), 54.

Levytska K, et al. (2025) Pegylated liposomal doxorubicin does not affect cardiac function in patients treated for gynecologic malignancies. *Gynecologic oncology reports*, 58, 101727.

Bao KK, et al. (2024) Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. *Breast (Edinburgh, Scotland)*, 73, 103612.

Vaynrub A, et al. (2024) Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer. *Cardio-oncology* (London, England), 10(1), 68.

Kilburn LB, et al. (2024) The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. *Nature medicine*, 30(1), 207.

Ghobadi A, et al. (2024) Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial. *Research square*.

Builoff V, et al. (2024) Evaluating AI Proficiency in Nuclear Cardiology: Large Language Models take on the Board Preparation Exam. *medRxiv : the preprint server for health sciences*.

Kusk MW, et al. (2024) Minimal dose CT for left ventricular ejection fraction and combination with chest-abdomen-pelvis CT. *European journal of radiology open*, 13, 100583.

Piscitelli J, et al. (2024) Evaluation of the effect of modafinil on the pharmacokinetics of encorafenib and binimetinib in patients with BRAF V600-mutant advanced solid tumors. *Cancer chemotherapy and pharmacology*, 94(3), 337.

Rustgi N, et al. (2024) Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers. *The oncologist*, 29(1), 15.

Mezzanotte-Sharpe J, et al. (2024) A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105). *Breast cancer research and treatment*, 207(2), 275.

Lewis GD, et al. (2024) The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. *Nature communications*, 15(1), 466.